Cell Biology Program

The Xuejun Jiang Lab

Research

Xuejun Jiang
Xuejun Jiang, PhD
Virginia and Daniel K. Ludwig Chair

The research of my laboratory focuses on two directions highly relevant to cancer biology, (1) the molecular basis of programmed cell death processes (including apoptosis and ferroptosis), and their roles in human disease; and (2) the molecular basis of autophagy and its role in cancer. We also study various cancer signaling and cellular metabolic events, especially those involved in cell death/survival determination. We aim to translate our basic research finding into potential therapeutic approaches. To achieve these goals, the laboratory utilizes a combination of approaches including biochemistry, chemical biology, proteomics, molecular cell biology, high-throughput screening, 3-dimensional microfluidic cell array, and mouse modeling.

View Lab Overview

Publications Highlights

People

Xuejun Jiang

Xuejun Jiang, PhD

Virginia and Daniel K. Ludwig Chair

  • Cell biologist Xuejun Jiang studies programmed cell death, molecular mechanisms, and their roles in tumorigenesis.
  • PhD, University of Texas Southwestern Medical Center at Dallas
jiangx@mskcc.org
Email Address
212-639-6814
Office Phone

Members

Zhixuan Bian
Research Fellow
Nicholas Carbone
Graduate Student, Tri-I PhD Program in Chemical Biology
Graduate Student, GSK
Maria Chui
Project Coordinator
Jiachen Hu
Graduate Student, GSK
Graduate Student, Tri-I PhD Program in Chemical Biology
Graduate Student, WCM
Pei Liu
Research Fellow
Xuesong Liu
Research Scholar
Atara Neugroschl
Graduate Student, Tri-I PhD Program in Chemical Biology
Nanfang Peng
Senior Research Scientist
Dazhi Wang
Research Scholar
Fahad Benthani
University Assistant at Johannes Kepler University
Scientist, International Flavors & Fragrances
Yan Feng, PhD
Principal Scientist, Accutar Therapeutics
Noor Gammoh, PhD
Group Leader - Reader, The University of Edinburgh
Programme Leader at MRC Protein Phosphorylation and Ubiquitylation Unit, University of Dundee
Minghui Gao
Principal Investigator and Professor, Harbin Institute of Technology
Associate Professor, Department of Biochemistry and Molecular Biology, Penn State Cancer Institute
Research Scientist, MSKCC
Postdoc Research Fellow at Ben Gurion University of the Negev, Israel
Manager of Regulatory Affairs Strategy, Regeneron Pharmaceuticals, Inc.
Deguang Liang, PhD
Assistant Investigator, Chinese Institutes for Medical Research Beijing
Alexander Minikes
Scientist, Lime Therapeutics
Prashant Monian
Principal Scientist at Wave Life Sciences, Boston, MA
Cindy Puente
Freelance, Medical Communications Consultant
President and Founder of Bon Opus Biosciences
Yuji Shi
R&D Director, HydroGene Therapeutics
Vice Director at Zhangjiagang Hospital
Drug Discovery Scientist, Bristol Myers Squibb
Hua Wang
Principal Investigator, Peking University International Cancer Center
Principal Investigator at Roswell Park Cancer Institute
Graduate Student, SUNY Downstate Health Sciences University
Pui-Mun Wong
Innovative Cell biology Researcher at National Singapore University
Jiao Wu, PhD
Professor at Fourth Military Medical University, Xi'an
Program Manager at Center Ministry of Science and Technology, China
Professor at Air Force Military Medical University, China
Graduate Student, WCMC
Exchange Graduate Student

Achievements

  • Louis and Allston Boyer Young Investigator Award for Basic Research, Memorial Sloan Kettering Cancer Center (2007)
  • Scholar, American Cancer Society (2007-2010)
  • Catherine and Frederick Adler Chair for junior faculty, Memorial Sloan Kettering Cancer Center (2006)
  • V Scholar, The V Foundation for Cancer Research (2004-2006 )
  • Alfred Bressler Scholar, Alref W. Bresller Scholars Fund (2004-2007)
  • Sigma Xi Award, UT Southwestern (1998)
  • Robert A. Welch Predoctoral Fellowship, UT Southwestern (1995-1999)

Open Positions

To learn more about available postdoctoral opportunities, please visit our Career Center

To learn more about compensation and benefits for postdoctoral researchers at MSK, please visit Resources for Postdocs

Career Opportunities

 

Apply now

Get in Touch

Disclosures

Members of the MSK Community often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community. These activities outside of MSK further our mission, provide productive collaborations, and promote the practical application of scientific discoveries.

MSK requires doctors, faculty members, and leaders to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public. Not all disclosed interests and relationships present conflicts of interest. MSK reviews all disclosed interests and relationships to assess whether a conflict of interest exists and whether formal COI management is needed.

Xuejun Jiang discloses the following relationships and financial interests:

  • Cold Spring Harbor Asia
    Professional Services and Activities
  • Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)
    Professional Services and Activities
  • Exarta Therapeutics
    Equity; Fiduciary Role / Position; Intellectual Property Rights; Professional Services and Activities (Uncompensated)
  • Lime Therapeutics, Inc.
    Equity; Professional Services and Activities (Uncompensated)
  • VivoZ Biolabs, LLC
    Intellectual Property Rights; Professional Services and Activities (Uncompensated)

The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.


This page and data include information for a specific MSK annual disclosure period (January 1, 2024 through disclosure submission in spring 2025). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.


View all disclosures